The idea of a “unicorn” — a company valued by venture capitalists at more than a billion dollars — is so seductive that some whole industries use it as a benchmark without understanding its irony. The mania of Silicon Valley is so great that the venture capital firms even got tired of “only” looking for unicorn companies, so they coined the painfully stupid word “decacorn,” which means “valued as 10 unicorns.”
When your aspirations are so disconnected from reality that even unicorns do not do it for you anymore, this is a clear sign that you’ve been drinking the Kool Aid.
The company Theranos has been the darling of Silicon Valley for years because it promises to “disrupt” healthcare testing, with disruption defined as the classic trifecta: that it will be cheaper, faster and better than the traditional ways.
Illustration: Mountain People
Theranos’ breakthrough technology claims to use just pinpricks of blood to get the results you used to need whole vials for. Also the tests get results incredibly fast, and would be rolled out at chain pharmacies across the US, changing the shape of medical testing forever. Did I mention that the tests would also be incredibly cheap?
It is claims like this, and support from venture capital firms, that have driven Theranos to a US$9 billion valuation. It is not intuitive that all this talk of valuation is simply calculated based on how much venture capital firms have invested. In other words, we say a company is “valued” at US$9 billion, and then act as though this is actual real money, but that number is based on nothing except what a venture capital firm felt the company was worth in a bet on the future.
MYTHS EXPOSED
The Oct. 15 Wall Street Journal expose of Theranos explodes the mythology of the company. Insiders who spoke to the Journal allege that out of the 240 kinds of tests it currently performs, the “pinprick” technology lauded as the linchpin of their strategy was only used for a tiny fraction of its testing.
Worse yet, there have been complaints to regulators from inside the company that their revolutionary tests are not giving results that agree with traditional testing, and that Theranos has been burying those unwanted results.
What has been blown open, again, is how little we truly know. Even though Theranos received regulatory approval, it is not clear at all if anyone truly knows how accurate their tests are.
The company responded to the story by stating: “Theranos’ technology is reviewed by regulators, proven in the field, and praised by leaders in the industry and doctors and individuals that we serve.”
This is why it is so important for us to sniff out unicorns when they make their way into our lives, and view them with the suspicion a mythological beast deserves.
Yes, Uber connects people and drivers — but it also short-circuits labor protections. Yes, Airbnb connects people for short term stays — but it also upends hotel regulations.
There is no such thing as a free lunch, and tech companies need to stop pretending they have discovered a way to both have and eat their cake through “sharing.”
Despite all these well-worn warning signs, the allegations against Theranos still shocked its many defenders.
A lot of the hype about Theranos is driven by its narrative: It has the young brilliant founder, Elizabeth Holmes, a Stanford dropout who founded the company at 19 and has a penchant for black turtlenecks. It has the cute origin story, too. You see, Holmes is afraid of needles, and it is that fear drove her to develop the pin-prick technology. And of course, the special technology that runs the special tests is called Edison, because when you’re making a mythology, a dollop of US exceptionalism never hurts.
Holmes has been on the cover of Fortune, profiled in the New Yorker and covered in all the right places. The fact that on paper she is worth billions causes her to be taken very seriously, because that is how this culture functions: Authority is created by money. From Ted talks to tech salons, she has been a prominent presence, and some have believed that her company could become the Google of healthcare testing.
And she fulfills all our personal checkmarks for the mythological quirks of genius. She does not date, is a vegan, sleeps very little, quotes Jane Austen by heart, works nonstop, dresses like Steve Jobs and as the New Yorker helpfully informs us: “Several times a day she drinks a pulverized concoction of cucumber, parsley, kale, spinach, romaine lettuce and celery.”
She sounds like someone who is tremendously fun to have at Scrabble night, and absolutely otherworldly; in fact, she sounds like a unicorn.
However, unlike mythical creatures, the allegations against her company are very real, and very ugly. Healthcare is not a new iPhone; people’s lives are on the line.
Employees allege in the Journal piece that some of the potassium levels seen in Theranos’ tests are so high that the person would have to be dead to give those results.
COMPARISON TEST
All this attention even caused Jean-Louis Gassee, a former Apple executive, to do a comparison test of his own with a blood test he is required to take monthly. Over two days having his blood tested traditionally and by Theranos yielded wildly different readings.
Gassee’s results are anecdotal, but it bears noting that this is not a beta program. He could check it out because Theranos is in use at pharmacies right now, and people use it every day to get real test results.
The company’s response has been to deny the allegations and to call the Wall Street Journal a tabloid. When that did not work, it published a rebuttal, but critics argue that it should publish its data in peer-reviewed journals if it wants to address the questions raised by the Journal.
This is the standard model of rapacious capitalism, fueled and developed in the tech sector. If medical testing were treated differently, it would damage its ability to “disrupt.”
How can Theranos be a decacorn if it does not deliver world-changing tests immediately at incredibly low cost?
There has to be unbearable pressure for the tests to work and work well, and if they do not perform perfectly, bury any dissent.
In retrospect, so much about Theranos seems suspect — the secretiveness of the company, the choice to have a majority of men like former US secretaries of state Henry Kissinger and George Schultz on the board of directors instead of health professionals, and the idea that a college dropout could found a company that could be the fountainhead from which a new way of doing all our medical testing springs forth.
Also, it is never wise to trust people who drink kale several times a day.
IRRATIONAL BEHAVIOR
The marketplace is as irrational as we are. It wants to believe the story that it wants to hear, and we all want unicorns to exist. That is why they are so lovely to us — because they exist only in the mind’s eye, in our dreams. We all want the world to be as simple as coding an app. We want to believe it is possible to codify all the variables, then address them one by one and then solve the equation.
Theranos is a perfect tech company name — it sounds mysterious, Greek and portentous. In Greek mythology Thanatos is Death. Could it be Death’s little-known brother, a minor Greek deity responsible for prescriptions and blood tests?
The reality is more prosaic. It has no larger mythology at all. It is simply an amalgam of the words “therapy” and “diagnosis.” That is it.
It sounds like it means a lot more than it actually does.
Two sets of economic data released last week by the Directorate-General of Budget, Accounting and Statistics (DGBAS) have drawn mixed reactions from the public: One on the nation’s economic performance in the first quarter of the year and the other on Taiwan’s household wealth distribution in 2021. GDP growth for the first quarter was faster than expected, at 6.51 percent year-on-year, an acceleration from the previous quarter’s 4.93 percent and higher than the agency’s February estimate of 5.92 percent. It was also the highest growth since the second quarter of 2021, when the economy expanded 8.07 percent, DGBAS data showed. The growth
In the intricate ballet of geopolitics, names signify more than mere identification: They embody history, culture and sovereignty. The recent decision by China to refer to Arunachal Pradesh as “Tsang Nan” or South Tibet, and to rename Tibet as “Xizang,” is a strategic move that extends beyond cartography into the realm of diplomatic signaling. This op-ed explores the implications of these actions and India’s potential response. Names are potent symbols in international relations, encapsulating the essence of a nation’s stance on territorial disputes. China’s choice to rename regions within Indian territory is not merely a linguistic exercise, but a symbolic assertion
More than seven months into the armed conflict in Gaza, the International Court of Justice ordered Israel to take “immediate and effective measures” to protect Palestinians in Gaza from the risk of genocide following a case brought by South Africa regarding Israel’s breaches of the 1948 Genocide Convention. The international community, including Amnesty International, called for an immediate ceasefire by all parties to prevent further loss of civilian lives and to ensure access to life-saving aid. Several protests have been organized around the world, including at the University of California Los Angeles (UCLA) and many other universities in the US.
Every day since Oct. 7 last year, the world has watched an unprecedented wave of violence rain down on Israel and the occupied Palestinian Territories — more than 200 days of constant suffering and death in Gaza with just a seven-day pause. Many of us in the American expatriate community in Taiwan have been watching this tragedy unfold in horror. We know we are implicated with every US-made “dumb” bomb dropped on a civilian target and by the diplomatic cover our government gives to the Israeli government, which has only gotten more extreme with such impunity. Meantime, multicultural coalitions of US